右雷佐生在血液肿瘤患者使用的用药模式分析

Analysis of dexrazoxane drug utilization in hematological tumor patients

目的分析右雷佐生在血液系统恶性肿瘤患者中的使用情况及存在的问题,为临床合理用药提供参考。方法回顾性分析某医院2019年7~9月使用右雷佐生的血液系统恶性肿瘤患者病历,提取人口学信息、疾病与用药信息和结局指标等数据并进行统计分析。结果在190例接受右雷佐生的血液系统恶性肿瘤患者中,非霍奇金淋巴瘤患者数量最多,占80.5%,使用最多的化疗方案为以CHOP为主的方案(55.8%)。结局指标进行相应描述性分析。188例患者的蒽环累积剂量未达到300 mg·m^(-2)。结论现状显示右雷佐生在在血液肿瘤中的使用时机较早。尽管有一些指南推荐右雷佐生在首次应用蒽环前使用,但仍需要高质量良好设计的临床研究,提供更好的循证医学证据,以支持临床用药。

Objective To analyze the current situation and potential problems in the use of dexrazoxane in patients with hematological malignancies,and to promote rational drug use in the clinic.Methods The medical records of patients with hematological malignancies who received dexrazoxane in a hospital from July to September in 2019 were retrospectively analyzed,and the patient demographic information,disease and medication information and outcome indicators were extracted and statistically analyzed.Results Among the 190 patients with hematological malignancies who received dexrazoxane,the number of patients with non-Hodgkin lymphoma was the largest,accounting for 80.5%,and the most frequently used chemotherapy regimen was CHOP(55.8%).Descriptive analysis was carried out for each outcome.The cumulative dose of anthracycline in 188 patients did not reach 300 mg·m^(-2).Conclusion Dexrazoxane is widely used in clinical practice of hematological tumors treatment,and the timing is earlier than the label recommendation.Although some guidelines recommend that dexrazoxane could be used before the first application of anthracycline,it still needs high-quality and well-designed clinical research to provide better evidence-based medicine evidence to support clinical decision.